Quince Therapeutics (NASDAQ:QNCX) Upgraded by Lifesci Capital to Strong-Buy Rating

Lifesci Capital upgraded shares of Quince Therapeutics (NASDAQ:QNCX) to a strong-buy rating in a report issued on Monday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings downgraded Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Zacks Research upgraded Quince Therapeutics to a “hold” rating in a report on Wednesday, June 24th. Wall Street Zen raised Quince Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th. Cantor Fitzgerald started coverage on Quince Therapeutics in a research note on Tuesday, June 23rd. They issued an “overweight” rating and a $80.00 price objective on the stock. Finally, Leerink Partners initiated coverage on Quince Therapeutics in a report on Wednesday, June 24th. They set an “outperform” rating and a $80.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $690.00.

Quince Therapeutics Stock Down 2.4%

NASDAQ:QNCX opened at $0.92 on Monday. The company has a market cap of $15.01 million, a P/E ratio of -0.09 and a beta of 1.40. Quince Therapeutics has a fifty-two week low of $0.79 and a fifty-two week high of $45.50. The firm’s 50 day moving average is $1.11 and its two-hundred day moving average is $9.47.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($11.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($26.00) by $14.20. Research analysts forecast that Quince Therapeutics will post -0.43 earnings per share for the current fiscal year.

Institutional Trading of Quince Therapeutics

Large investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new position in shares of Quince Therapeutics during the second quarter worth about $37,000. Intellectus Partners LLC acquired a new position in Quince Therapeutics during the 4th quarter worth approximately $179,000. Bridgeway Capital Management LLC lifted its position in Quince Therapeutics by 20.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock worth $212,000 after acquiring an additional 22,200 shares in the last quarter. Hudson Bay Capital Management LP purchased a new position in Quince Therapeutics in the 4th quarter worth approximately $213,000. Finally, Quadrature Capital Ltd purchased a new position in Quince Therapeutics in the 4th quarter worth approximately $268,000. 30.75% of the stock is currently owned by institutional investors and hedge funds.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.